Carlos E. Baena Cagnani Grant: Best Publication in the Asthma Research and Practice
To honor the memory of its Past President Professor Carlos E. Baena Cagnani, the WCA-2016 will award the “Carlos E. Baena Cagnani Grant” to the Global Asthma Association-INTERASMA Member who has published the Best Article in the Asthma Research and Practice Journal
• The applicant should be a GAA-INTERASMA Member the last four (4) years.
• The applicant should have already published an article in the “Asthma Research and Practice” Journal
The WCA-2016 will award a Communication Grant to a GAA-INTERASMA Member who has most promoted the Organization and its goals through the Internet and social media.
• The applicant should be a GAA-INTERASMA Member for the last five (5) years.
• The applicant needs to have already submitted articles for publication in the GAA-INTERASMA website.
Exercise-induced bronchoconstriction: new evidence in pathogenesis, diagnosis and treatment
The acute airway narrowing that occurs as a result of exercise is defined exercise-induced bronchoconstriction (EIB). Most recent guidelines recommend distinguishing EIB with underlying clinical asthma (EIB A ) from the occurrence of bronchial obstruction in subjects without other symptoms and signs of asthma (EIBw A ). EIB has been in fact reported in up to 90 % of asthmatic patients, reflecting the level of disease control, but it may develop even in subjects without clinical asthma, particularly in children, athletes, patients with atopy or rhinitis and following respiratory infections. Both EIB A and EIBw A have peculiar pathogenic mechanisms, diagnostic criteria and responses to treatment and prevention. The use of biomarkers, proteomic approaches and innovative technological procedures will hopefully contribute to better define peculiar phenotypes and to clarify the role of EIB as risk factor for the development of asthma, as well as an occupational disease.
New article has just been published in Asthma Research and Practice
Despite the regular treatment with inhaled corticosteroids (ICS) or ICS plus long-acting beta2-agonists, permits to control de majority of asthmatics, a significant proportion of patients does not respond to this treatment.
This review was aimed to explore the role of psychological factors associated to the unsuccessful fulfilment of optimal levels of asthma control, especially in patients suffering from severe asthma. The results of a Medline search were 5510 articles addressed to different psychological key concepts, constructs and variables. This review will highlight how some selected psychological factors may have a burden on asthma management. Evidences are now available about the link between asthma (in terms of severity and control), some psychological aspects (subjective perception, alexithymia, coping style) and mental health (anxiety, depression). Taking into account this most probably bidirectional influence, a screening of mental symptoms and psychological aspects related to asthma, could lead to plan appropriate interventions to better control asthma and to improve the patient’s well-being.
23rd World Congress of Asthma - WCA-2016
Dear colleagues and friends
It is my privilege and honor to invite you to participate in the 23rd World Congress of Asthma - WCA-2016 in Madrid, Spain, organized by the Asthma Global Association-INTERASMA, from March 12 through March 15, 2016. This congress is supported by the Spanish societies: SEPAR (Sociedad Española de Neumología y Cirugía Torácica), SEAIC (Sociedad Española de Alergología e Inmunología Clínica), SEICAP (Sociedad Española de Alergia, Inmunología Clínica, Asma y Alergia Pediátrica) and Spanish Pediatric Association (AEP) whose members are welcome.
WCA brings together specialists, physicians, and healthcare professionals from all over the world to share valuable scientific knowledge on asthma, ranging from diagnostic and therapeutic tools and techniques to leading-edge research. WCA has been very popular resulting in highly successful well attended congresses with outstanding state-of-the-art scientific programs.
The 23rd World Congress of Asthma - WCA-2016 will not be an exception; we plan to produce a great scientific program once again. The INTERASMA is celebrating its 60th anniversary of uninterrupted education in the field of asthma, making it the most important international asthma and related diseases organization in the world, as well as a reference organization for primary care physicians, healthcare providers and medical students.
Madrid, the majestic capital of Spain, is one of the most beautiful cities in Europe and it is famous for its rich heritage and culture, hosting important museums with masterpieces of art through centuries of exciting history. Today, Madrid is an economic, financial, administrative and cultural destination, offering great hospitality, infrastructure, great culinary tradition, and a very attractive night life. We look forward to welcoming you in Madrid, Spain, in 2016.
|Professor Giorgio Walter Canonica
President of INTERASMA
Read our inaugural articles and submit your next manuscript
Follow BioMed Central:
How to ensure BioMed Central's emails reach your inbox.
You have received this message because you have asked for updates from Asthma Research and Practice.
To change your email preferences please login to: http://www.asthmarp.com/my/details/interests
To unsubscribe as a registrant please visit our journal unsubscribe page.
Allergen immunotherapy in asthma; what is new?
The use and role of allergen immunotherapy (AIT) in asthma is still a matter of debate, and no definite recommendation about this is made in guidelines, both for the subcutaneous and sublingual routes. This is essentially due to the fact that most controlled randomised trials were not specifically designed for asthma, and that objective measures of pulmonary function were only occasionally considered. Nonetheless, in many trials, favourable results in asthma (symptoms, medication usage, bronchial reactivity) were consistently reported. There are also several meta analyses in favour of AIT, although their validity is limited by a relevant methodological heterogeneity. In addition to the crude clinical effect, a disease modifying action of AIT (prevention of asthma onset and long-lasting effects) have been reported. The safety is an important aspect to consider in asthma. Fatalities were rare: in Europe no fatality was reported in the last three decades, as in the United States in the last 4 years. Based on previous surveys, and common sense, uncontrolled asthma is still recognized as the most important risk factor for severe adverse events. On the contrary, there is no evidence that AIT can worsen or induce asthma. According to the available evidence, AIT can be safely used as add-on treatment when asthma is associated with rhinitis (a frequent condition), provided that asthma is adequately controlled by pharmacotherapy. AIT cannot be recommended or suggested as single therapy. When asthma is the unique manifestation of respiratory allergy, its use should be evaluated case by case.
Allergen immunotherapy; Sublingual immunotherapy; Subcutaneous immunotherapy; Efficacy; Safety; Allergic asthma; Allergic rhinitis; Adverse events
The following new article has just been published in Asthma Research and Practice
Bonini M, Palange P
Asthma Research and Practice 2015, 1 :2 (2 July 2015)
Asthma Research and Practice: the official journal of Interasma
Dear Society member,
We are very pleased to inform you that Asthma Research and Practice (ARP) has now officially launched and published its first articles. ARP is the official journal of Interasma – the Global Asthma Association and is led by joint Editors-in-Chief, Juan Celedón (USA) and Giovanni Passalaqua (Italy). The Open Access, peer-reviewed journal aims to spread international awareness and knowledge about the growing burden of asthma by publishing basic, clinical and translational research concerning asthma and related disorders.
ARP aims to serve as an international platform for the dissemination of research of interest to pulmonologists, allergologists, primary care physicians and family doctors, ENTs and other health care providers interested in asthma, its mechanisms and comorbidities.
You can read all of the publications, including the launch Editorial, on the journal website: www.asthmarp.com/content. The journal will be published continuously online-only and so we encourage you to sign up to receive free email alerts to keep up to date with all of the latest research. You can do this by registeringhere.
As an Interasma society member, please do help us spread the word about the journal by encouraging colleagues to submit their manuscripts and by submitting high quality work yourself. Don’t forget we have also have a range of materials available to help you support us in letting people know about the journal, www.asthmarp.com/about/promote for example if you are attending any meetings relevant to the journal’s scope.
Thank you for your support so far, we look forward to working with you to build the success of Asthma Research and Practice!
With best wishes,
Juan Celedón, jointEditor-in-Chief
Giovanni Passalacqua, jointEditor-in-Chief
Journal Development Editor
236 Gray's Inn Road
London, WC1X 8HB
T: +44 (0)20 3192 2153
The patient with rhinitis in the pharmacy. A cross-sectional study in real life
In the practical management of allergic rhinitis (AR), pharmacists are usually the first-line contact, also because some medications are available as over the counter. Therefore, pharmacists may represent an important resource, in mediating the interaction between patients and physicians. We evaluated the clinical/demographic characteristics of patients with respiratory allergies who consulted their pharmacists as first-line contact. A patient-oriented questionnaire was developed by a scientific committee including pharmacists, GPs, allergists, pulmonologists and ENT specialists.
The questionnaire consisted of items covering the general aspects of AR. Allergic Rhinitis and its Impact on Asthma guidelines were assumed as reference for diagnosis and therapy. The questionnaire was distributed to pharmacies, and pharmacists were asked to deliver the questionnaire to all patients referring for nasal symptoms.
30 pharmacies were involved during the pollen season 2011, and 410 patients (55 % male) participated. The most frequent complaints were 20 rhinitis (49 %) and conjunctivitis (29 %), followed by lower respiratory symptoms (cough and/or dyspnea). Isolated conjunctival symptoms were present in only 22 % of patients. Among patients with lower respiratory symptoms, cough was the most frequent, variously associated with upper respiratory symptoms or overt dyspnea. Dyspnea alone was present in 16 % of patients. 39 % of patients had no physician-based diagnosis. Oral antihistamines were the most used self-medication, followed by intranasal decongestants. 30 % of respondents had used alternative medicines.
According to these data, AR is still considered a trivial disease, frequently self-managed, with over the counter medications, not in line with guidelines. A physician-based diagnosis is present in about 60 % of patients.
Respiratory allergy; Allergic rhinitis; Allergic asthma; Pharmacist
Asthma and obesity: mechanisms and clinical implications
Obesity is the most common asthma co-morbidity; it has been associated with increased risk for asthma exacerbations, worse respiratory symptoms and poor control. The exact mechanisms remain elusive and are probably multifactorial, stemming from mechanical alterations of the airways and lung parenchyma, to systemic and airway inflammatory and metabolic dysregulation that adversely influences lung function and or response to therapy. However, the fact that not every obese asthmatic is equally affected by weight gain highlights the many challenges and complexities in understanding this association. The factors that determine susceptibility may not depend on being obese alone, but rather the interactions with other phenotypical characteristics, such as age of asthma onset, gender and race to name a few. Inability to account for asthma phenotypes that are differentially affected by increasing body mass index (BMI) may contribute to the lack of consistent results across studies. This review will provide a succinct summary of obesity-related mechanisms and the clinical impact on asthma including highlights on recent progress.